Industry: Cancer therapies and diagnostics
Arestyr OncoLogic is a biotech company developing both diagnostics and therapies for cancer. The company’s proprietary technology is based on its unique understanding of a specific molecular structure found in late-stage cancer cells. Arestyr’s technology targets these cells by generating an immune response in the form of antibodies. The antibodies then serve as a biomarker to show where the cancer cells are located.
Globally, the cancer biomarker market is valued at about $30 billon annually. Arestyr plans to market its unique product to diagnostics companies, biotech companies and financial buyers.